Ap24
AMENDMENT
FORM 38.5(a)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(a) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS AND DEALING IN A CLIENT-SERVING CAPACITY
1. KEY INFORMATION
Name of exempt principal trader |
J.P. Morgan Securities Plc |
Company dealt in |
UDG Healthcare Plc |
Class of relevant security to which the dealings being disclosed relate (Note 1) |
|
Date of dealing |
9 August 2021 |
2. DEALINGS (Note 2)
(a) Purchases and sales
Total number of relevant securities acquired |
Highest price paid (Note 3) |
Lowest price paid (Note 3) |
370,561(New Borrow)* 571,520 |
N/A |
N/A |
Total number of securities disposed |
Highest price received (Note 3) |
Lowest price received (Note 3) |
112,823 |
|
|
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD |
Nature of transaction (Note 4) |
Number of relevant securities (Note 5) |
Price per unit (Note 3) |
Equity Swap |
Decrease Long
Increase Long
Increase Short
Opening a long position
Opening a short position |
1,774 19,717 474 2,443 354
502 860 25,559 7,468 23,981 1,179 16,782
13,700
2,745
333,333 |
|
Ap25
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option |
Writing, selling, purchasing, varying etc. |
Number of securities to which the option relates (Note 5) |
Exercise price |
Type, e.g. American, European etc. |
Expiry date |
Option money paid/received per unit (Note 3) |
|
|
|
|
|
|
|
(ii) Exercising
Product name, e.g. call option |
Number of securities |
Exercise price per unit (Note 3) |
|
|
|
3. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the
voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition
or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
Date of disclosure |
12 August 2021 |
Contact name |
Alwyn Basch |
Telephone number |
020 7742 7407 |
Name of offeree/offeror with which connected |
UDG Healthcare Plc |
Nature of connection (Note 6) |
Financial adviser to CD&R Fund XI |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.